Navigation Links
PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
Date:6/9/2008

HUNDREDS OF CUSTOMER HOSPITALS USING ELECTRONIC 222 TO ORDER CLASS II

CONTROLLED SUBSTANCES

SEATTLE, June 9 /PRNewswire/ -- PharMEDium Services, LLC, the leading provider of outsourced hospital pharmacy I.V. compounded solutions, has expanded its first-in-the-industry electronic 222 (e-222) ordering initiative, which enables virtually real-time ordering of Schedule II Controlled Substances versus the more time-consuming traditional process, to all hospitals nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051202/PHARMEDIUMLOGO)

The company announced the initiative at the American Society of Health-System Pharmacists' Summer Meeting and exhibition here.

Hundreds of customers are now ordering pain management medications through PharMEDium's e-222 system, which applies to the entire line of its pain management services. "Our expansion of e-222 represents an ongoing commitment to patient safety, quality, and superior customer service. The early and fast adoption by our customers represents their partnership with us in helping make e-222 a standard practice across our industry," said David Jonas, PharMEDium's Chairman and Chief Executive Officer.

PharMEDium's new controlled substance ordering system aligns with the efforts of the U.S. Drug Enforcement Administration (DEA) and drug industry leaders to take advantage of e-commerce tools to improve efficiency and effectiveness associated with controlled substances ordering. DEA requires a Form 222 for all orders of Schedule II Controlled Substances, which until recently could only be processed through paper forms. E-222 ordering takes about 20 seconds, versus about 20 minutes for paper orders, according to DEA's Office of Diversion Control (ODC). In addition, the elimination of the paper Form 222 reduces the time it takes to receive an order by one to two days. Hospitals interested in e-222 must obtain a digital certificate from the DEA to participate, which typically takes 30 days from application to approval.

"E-222 ordering has significant benefits," said Susan Groth, Pharmacy Buyer at Methodist Hospital in St. Louis Park, MN. "This initiative makes the ordering process faster and easier, in addition to reducing errors and rework," Groth added.

"E-222 is one element of PharMEDium's online customer service offering available on the company's website," Jonas said. "In addition to online ordering, PharMEDium's customers can obtain order status information, track shipments, and review invoice history at pharmedium.com. These value-added features were developed based on extensive customer feedback and provide a multitude of time- and resource-saving benefits. PharMEDium is committed to deploying new and innovative online functionality to provide our customers with world-class customer service," Jonas added.

About PharMEDium Services, LLC

For more than 15 years, PharMEDium has been the leading provider of outsourced compounding services. In that time, PharMEDium has grown into a nationwide network of state licensed and federally registered compounding centers providing trusted solutions to more than 1,800 hospitals throughout the United States. Managed by licensed pharmacists and staffed by certified technicians, the company complies with all applicable state laws and FDA regulations, including USP Chapter < 797 > and DEA requirements.

Contact: Amy Langan, MEDIA INQUIRIES: Jon Ross,

PharMEDium Director of Marketing Ross Consulting &

847/457-2327 Communications

Email: info@pharmedium.com 773-271-0677

jross1chi@prodigy.net


'/>"/>
SOURCE PharMEDium Services, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PharMEDium Announces Electronic 222 Ordering Initiative
2. PharMEDium Announces Availability of Pre-Filled Operating Room Perioperative Compounded Drugs
3. Senetek PLC Announces Key Personnel Appointments
4. QLT announces agreement to sell Aczone(R) to Allergan for approximately US$150 million
5. Health Robotics Announces IV Station (TM Pending) a Centrally-Controlled,
6. Universal Health Realty Income Trust Announces Dividend Increase
7. Fort Dodge Animal Health Announces Reintroduction of ProHeart 6 to the U.S. Veterinary Market
8. American Heartworm Society Announces Heartworm Incidence Survey
9. Nuvelo Announces Publication of Preclinical Data From Wnt Therapeutics Program
10. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
11. DTC Perspectives, Inc. Announces the New DTC Hall of Fame Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Center for ... for caregivers of those affected by autism spectrum disorder (ASD) and other developmental disabilities. ... Seals Maine, will give parents and other caregivers the opportunity to share stories and ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of two ostomy patients, standing as living proof that attitude and determination can ... diseases and issues that spike around the holidays. This campaign will offer patients ...
(Date:12/2/2016)... ... 02, 2016 , ... More than half of American teens report losing their ... speaking with their child about sex related topics, less than 60 percent spoke about ... to announce the launch of its second edition of the “Sexual Wellness” campaign, aiming ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
Breaking Medicine Technology: